Surgical strategy for the management of sacral giant cell tumors: a 32-case series

被引:18
作者
Li, Guodong [1 ]
Fu, Dong [1 ]
Chen, Kai [1 ]
Ma, Xiaojun [1 ]
Sun, Mengxiong [1 ]
Sun, Wei [1 ]
Li, Jian [1 ]
Cai, Zhendong [1 ]
机构
[1] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Orthopaed, Shanghai 200072, Peoples R China
基金
上海市自然科学基金;
关键词
Giant cell tumor; Sacrum; Surgical treatment; ARTERIAL EMBOLIZATION; CONSERVATIVE SURGERY; FOLLOW-UP; BONE; CRYOSURGERY; CURETTAGE; SPINE; TERM;
D O I
10.1016/j.spinee.2012.06.014
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BACKGROUND CONTEXT: Surgical treatment of sacral giant cell tumors (GCTs) is associated with a high rate of complications, and there is controversy over which type of surgical treatment is optimal. PURPOSE: To develop an optimal treatment strategy for sacral GCTs. STUDY DESIGN/SETTING: Retrospective/academic medical center. PATIENT SAMPLE: A total of 32 patients (18 women and 14 men) with sacral GCT who underwent surgery between August 1996 and August 2008. OUTCOME MEASURES: Local recurrence rate, surgical margins, blood loss, sacral nerve root preservation, and complications. METHODS: The medical charts of 32 patients were reviewed. RESULTS: Patients underwent either wide resection (n=2), marginal resection (n=11), marginal resection plus curettage (n=12), or curettage alone (n=7). The curettage group and the wide resection group had the highest and lowest amounts of blood loss (4,500 vs. 1,300 mL, respectively). During follow-up (median, 42 months), 12 patients (37.5%) had local recurrence, including five of seven in the curettage group. The recurrence rate was significantly lower in the marginal excision group compared with that in the curettage group (18.2% vs. 71.4%, respectively; p=.049). Five patients had bladder dysfunction, and two patients had bowel dysfunction. Four patients who underwent marginal resection had lower limb dysfunction. Overall survival was 93.6%, and 2-year recurrence-free survival was 84.4%. CONCLUSIONS: Choosing an optimal surgical margin in the treatment of sacral GCTs is of great importance for local recurrence control and sacral nerve root preservation. Curettage alone should not be used to treat sacral GCT. (c) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:484 / 491
页数:8
相关论文
共 19 条
  • [1] Cai ZhengDong Cai ZhengDong, 2008, Chinese Journal of Orthopaedics, V28, P101
  • [2] Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone
    Cheng, YY
    Huang, L
    Lee, KM
    Xu, JK
    Zheng, MH
    Kumta, SM
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2004, 75 (01) : 71 - 77
  • [3] Gibbs Iris C, 2003, Neurosurg Focus, V15, pE8
  • [4] Outcome of Conservative Surgery for Giant Cell Tumor of the Sacrum
    Guo, Wei
    Ji, Tao
    Tang, Xiaodong
    Yang, Yi
    [J]. SPINE, 2009, 34 (10) : 1025 - 1031
  • [5] Serial arterial embolization for large sacral giant-cell tumors - Mid- to long-term results
    Hosalkar, Harish S.
    Jones, Kristofer J.
    King, Joseph J.
    Lackman, Richard D.
    [J]. SPINE, 2007, 32 (10) : 1107 - 1115
  • [6] Role of adjuvant cryosurgery in intralesional treatment of sacral tumors - Results of a 3-11-year follow-up
    Kollender, Y
    Meller, I
    Bickels, J
    Flusser, G
    Issakov, J
    Merimsky, O
    Marouani, N
    Nirkin, A
    Weinbroum, AA
    [J]. CANCER, 2003, 97 (11) : 2830 - 2838
  • [7] Giant cell tumor of the pelvis and sacrum - 17 cases and analysis of the literature
    Leggon, RE
    Zlotecki, R
    Reith, J
    Scarborough, MT
    [J]. CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2004, (423) : 196 - 207
  • [8] Long-term follow-up of patients with giant cell tumor of the sacrum treated with selective arterial embolization
    Lin, PP
    Guzel, VB
    Moura, MF
    Wallace, S
    Benjamin, RS
    Weber, KL
    Morella, FA
    Gokaslan, ZL
    Yasko, AW
    [J]. CANCER, 2002, 95 (06) : 1317 - 1325
  • [9] MARCOVE RC, 1994, CANCER, V74, P1253, DOI 10.1002/1097-0142(19940815)74:4<1253::AID-CNCR2820740412>3.0.CO
  • [10] 2-9